Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06375109
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-19
First Post:
2024-04-16
Brief Title:
PD-L1PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC
Sponsor:
Beijing Chest Hospital Capital Medical University
Organization:
Beijing Chest Hospital Capital Medical University
Study Overview
Official Title:
PD-L1PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer an Open-label Non-randomized Controlled Phase II Single-center Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NeoSCLC-001
Brief Summary:
This is an open-label non-randomized controlled single-center phase II study to compare the efficacy and safety of neoadjuvant PD-L1PD-1 inhibitor chemotherapy carboplatincisplatin etoposide with chemotherapy carboplatincisplatin etoposide alone followed by radical surgery and adjuvant treatment as perioperative therapy in patients with limited-stage SCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NeoSCLC-001 | OTHER | Beijing Chest Hospital Capital Medical University | None |